HRP20171190T1 - Protutijelo protiv beta-amiloida i njegove upotrebe - Google Patents
Protutijelo protiv beta-amiloida i njegove upotrebe Download PDFInfo
- Publication number
- HRP20171190T1 HRP20171190T1 HRP20171190TT HRP20171190T HRP20171190T1 HR P20171190 T1 HRP20171190 T1 HR P20171190T1 HR P20171190T T HRP20171190T T HR P20171190TT HR P20171190 T HRP20171190 T HR P20171190T HR P20171190 T1 HRP20171190 T1 HR P20171190T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- antigen
- binding fragment
- beta
- amyloid
- Prior art date
Links
- 239000012634 fragment Substances 0.000 claims 20
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 239000013604 expression vector Substances 0.000 claims 5
- 239000000463 material Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 230000007082 Aβ accumulation Effects 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000005298 paramagnetic effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000002600 positron emission tomography Methods 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 239000012857 radioactive material Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Optics & Photonics (AREA)
- Mycology (AREA)
Claims (17)
1. Izolirano ljudsko protutijelo ili njegov fragment koji veže antigen koje se veže na beta-amiloid, naznačeno time da protutijelo ili njegov fragment koji veže antigen sadrži:
varijabilnu regiju teškog lanca sa aminokiselinskom sekvencom prikazanom u SEQ ID NO: 39; te varijabilnu regiju lakog lanca sa aminokiselinskom sekvencom prikazanom u SEQ ID NO: 41.
2. Protutijelo ili njegov fragment koji veže antigen prema zahtjevu 1, naznačeno time da je ljudski IgG izotip protutijela.
3. Protutijelo ili njegov fragment koji veže antigen prema zahtjevu 1, naznačeno time da je ljudski IgG1 izotip protutijela.
4. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 3, naznačeno time da protutijelo sadrži ljudski kapa laki lanac.
5. Protutijelo ili njegov fragment koji veže antigen prema zahtjevu 1, naznačeno time da se fragment koji veže antigen bira iz skupine koja sadrži jednolančani Fv fragment, F(ab') fragment, F(ab) fragment, i F(ab')2 fragment.
6. Izolirani polinukleotid naznačen time da kodira protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5.
7. Ekspresijski vektor naznačen time da sadrži polinukleotid prema zahtjevu 6.
8. Izolirana stanica domaćina naznačena time da sadrži ekspresijski vektor prema zahtjevu 7, ili dva ekspresijska vektora, pri čemu prvi ekspresijski vektor kodira varijabilnu regiju teškog lanca i drugi ekspresijski vektor kodira varijabilnu regiju lakog lanca protutijela ili njegovog fragmenta koji veže antigen prema bilo kojem od zahtjeva 1 do 5.
9. Postupak za pripravu anti-beta-amiloidnog antitijela ili njegovog fragmenta koji veže antigen, naznačen time da navedeni postupak obuhvaća
(a) kultiviranje stanice domaćina prema zahtjevu 8 u kulturi stanica; i
(b) izoliranje anti-beta-amiloidnog protutijela ili njegovog fragmenta koji veže antigen iz stanične kulture.
10. Protutijelo ili njegov fragment koji veže antigen koje je kodirano polinukleotidom prema zahtjevu 6 ili se može dobiti postupkom prema patentnom zahtjevu 9.
11. Protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 ili 10 naznačeno time da je za uporabu za liječenje Alzheimerove bolesti, blagog kognitivnog poremećaja, ili abnormalnog nakupljanja ili taloženja beta-amiloida u središnjem živčanom sustavu kod čovjeka.
12. Protutijelo ili njegov fragment koji veže antigen za uporabu prema zahtjevu 11, naznačeno time da se protutijelo ili njegov fragment koji veže antigen primjenjuje intravenozno, intramuskularno, subkutano, intraperitonealno, intranazalno, parenteralno ili kao aerosol.
13. Farmaceutski pripravak naznačen time da sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 ili 10 i farmaceutski prihvatljiv nosač.
14. Pripravak naznačen time da sadrži protutijelo ili njegov fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 5 ili 10 vezan na detektabilnu oznaku.
15. Pripravak prema zahtjevu 14, naznačen time da detektabilna oznaka je enzim, protetska skupina, fluorescentni materijal, luminescentni materijal, bioluminiscentni materijal, radioaktivni materijal, metal koji emitira pozitron, ili neradioaktivni paramagnetski metalni ion.
16. Pripravak prema zahtjevu 14 ili 15 naznačen time da je za uporabu za in vivo otkrivanje nakupljanja beta-amiloida u mozgu ljudskog subjekta.
17. Pripravak za uporabu prema zahtjevu 16, naznačen time da se nakupljanja beta-amiloida otkriva pomoću pozitronske emisijske tomografije.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87883107P | 2007-01-05 | 2007-01-05 | |
EP07000211 | 2007-01-05 | ||
US93429107P | 2007-06-11 | 2007-06-11 | |
EP07020341 | 2007-10-17 | ||
EP11185486.5A EP2436696B8 (en) | 2007-01-05 | 2008-01-07 | Anti-beta-amyloid antibody and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20171190T1 true HRP20171190T1 (hr) | 2017-10-20 |
Family
ID=43480381
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140049AT HRP20140049T1 (hr) | 2007-01-05 | 2014-01-16 | Anti beta-amiloid antitijela i njihova upotreba |
HRP20171190TT HRP20171190T1 (hr) | 2007-01-05 | 2017-08-02 | Protutijelo protiv beta-amiloida i njegove upotrebe |
HRP20171440TT HRP20171440T1 (hr) | 2007-01-05 | 2017-09-26 | Postupak za dobivanje molekula i meta za vezanje specifičnih za određene bolesti |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140049AT HRP20140049T1 (hr) | 2007-01-05 | 2014-01-16 | Anti beta-amiloid antitijela i njihova upotreba |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20171440TT HRP20171440T1 (hr) | 2007-01-05 | 2017-09-26 | Postupak za dobivanje molekula i meta za vezanje specifičnih za određene bolesti |
Country Status (6)
Country | Link |
---|---|
US (11) | US9670272B2 (hr) |
JP (6) | JP2012139219A (hr) |
CO (1) | CO6230998A2 (hr) |
CY (1) | CY1114953T1 (hr) |
HR (3) | HRP20140049T1 (hr) |
IL (2) | IL199534A (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
ES2544569T3 (es) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Autoanticuerpos humanos anti alfa-sinucleina |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
AU2013302540B2 (en) | 2012-08-16 | 2018-02-15 | Ipierian, Inc. | Methods of treating a tauopathy |
US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
WO2015122922A1 (en) | 2014-02-14 | 2015-08-20 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
HUE042815T2 (hu) | 2014-09-30 | 2019-07-29 | Diadem S R L | Humán P53 lineáris epitópot kötõ antitest és diagnosztikai alkalmazásai |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
US11135313B2 (en) * | 2015-10-28 | 2021-10-05 | The Trustees Of The University Of Pennsylvania | Intrathecal administration of adeno-associated-viral vectors for gene therapy |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
JP6149977B1 (ja) | 2016-06-10 | 2017-06-21 | 住友電気工業株式会社 | 電圧変換装置及び漏れインダクタンス決定方法 |
TW201827467A (zh) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | 焦穀胺酸類澱粉蛋白-β之抗體及其用途 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2019040612A1 (en) | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES |
JP7466459B2 (ja) | 2018-04-17 | 2024-04-12 | セルデックス セラピューティクス インコーポレイテッド | 抗cd27および抗pd-l1抗体ならびに二重特異性構築物 |
US11236155B2 (en) | 2019-03-26 | 2022-02-01 | Janssen Pharmaceutica Nv | Antibodies to pyroglutamate amyloid-β and uses thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
JP2023514727A (ja) | 2020-02-21 | 2023-04-07 | シルバーバック セラピューティックス インコーポレイテッド | ネクチン-4抗体コンジュゲートおよびその使用 |
JP2023516388A (ja) * | 2020-03-05 | 2023-04-19 | メモリアル スローン ケタリング キャンサー センター | 抗ccr8剤 |
CA3183993A1 (en) | 2020-07-01 | 2022-01-06 | Peter R. Baum | Anti-asgr1 antibody conjugates and uses thereof |
CN116348487A (zh) | 2020-07-23 | 2023-06-27 | 欧萨尔普罗席纳有限公司 | 抗淀粉样β抗体 |
CN112308761A (zh) * | 2020-11-13 | 2021-02-02 | 济南浪潮高新科技投资发展有限公司 | 基于切片与插值的机器人深度相机点云降采样滤波方法 |
US20220304946A1 (en) * | 2021-03-28 | 2022-09-29 | Muhammad Imran Khan | Trans-anethole ((e)-1-methoxy-4- (1-propenyl) benzene), a new and potent inhibitor of prolyl endopeptidase |
WO2022261510A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
WO2023081194A2 (en) * | 2021-11-03 | 2023-05-11 | Biogen Ma Inc. | Methods for treating alzheimer's disease |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
JPH09507746A (ja) | 1993-10-27 | 1997-08-12 | アテナ ニューロサイエンシズ,インコーポレイティド | Swedish変異を有するAPP対立遺伝子を含有するトランスジェニック動物 |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
US20020086847A1 (en) | 1997-04-09 | 2002-07-04 | Mindset Biopharmaceuticals (Usa) | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
US6703015B1 (en) | 1999-09-03 | 2004-03-09 | Ramot At Tel-Aviv University Ltd. | Filamentous bacteriophage displaying an β-amyloid epitope |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US7462605B2 (en) | 1998-01-23 | 2008-12-09 | Celmed Oncology (Usa), Inc. | Phosphoramidate compounds and methods of use |
WO1999050300A1 (en) | 1998-03-30 | 1999-10-07 | The Trustees Of The University Of Pennsylvania | Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
US6436401B1 (en) | 1999-09-14 | 2002-08-20 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies |
US6187309B1 (en) | 1999-09-14 | 2001-02-13 | Milkaus Laboratory, Inc. | Method for treatment of symptoms of central nervous system disorders |
US6713058B2 (en) | 1999-09-14 | 2004-03-30 | Milkhaus Laboratory, Inc. | Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
US6294171B2 (en) | 1999-09-14 | 2001-09-25 | Milkhaus Laboratory, Inc. | Methods for treating disease states comprising administration of low levels of antibodies |
EP1232283B1 (fr) | 1999-10-27 | 2006-05-24 | Université de Liège | Immuno PCR en temps réel utilisant un ADN-chimère comme marqueur d'amplification |
DE60140252D1 (de) | 2000-06-22 | 2009-12-03 | Genentech Inc | Agonistische monoklonale antikörper gegen trkc |
AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
EP1172378A1 (en) | 2000-07-12 | 2002-01-16 | Richard Dr. Dodel | Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
EP1944040B1 (en) | 2001-08-17 | 2012-08-01 | Washington University | Assay method for Alzheimer's disease |
US7414111B2 (en) | 2001-09-19 | 2008-08-19 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
GB0203446D0 (en) | 2002-02-14 | 2002-04-03 | Univ Lancaster | Detection and/or monitoring of synuclein-related diseases |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
KR100994748B1 (ko) | 2002-04-19 | 2010-11-17 | 더 가버닝 카운실 오브 더 유니버시티 오브 토론토 | 알쯔하이머병의 치료를 위한 면역학적 방법 및 조성물 |
US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
ATE455853T1 (de) | 2002-11-22 | 2010-02-15 | Chugai Pharmaceutical Co Ltd | Antikörper gegen geschädigtes gewebe |
US20060240485A1 (en) * | 2003-04-24 | 2006-10-26 | Universitat Zurich | Method of monitoring immunotherapy |
TWI374893B (en) | 2003-05-30 | 2012-10-21 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
CA2528182A1 (en) * | 2003-06-06 | 2005-06-16 | Oncomax Acquisition Corp. | Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
WO2005018424A2 (en) | 2003-08-18 | 2005-03-03 | Research Foundation For Mental Hygiene, Inc. | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
US20060094064A1 (en) | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
PT1720909E (pt) | 2004-02-23 | 2011-12-23 | Lilly Co Eli | Anticorpo anti-a¿ò |
ES2367311T3 (es) | 2004-04-15 | 2011-11-02 | University Of Florida Research Foundation, Inc. | Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales. |
JPWO2005105998A1 (ja) | 2004-04-27 | 2008-07-31 | 財団法人化学及血清療法研究所 | ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント |
WO2005120571A2 (en) | 2004-06-07 | 2005-12-22 | Ramot At Tel Aviv University Ltd. | Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
US20060062859A1 (en) | 2004-08-05 | 2006-03-23 | Kenneth Blum | Composition and method to optimize and customize nutritional supplement formulations by measuring genetic and metabolomic contributing factors to disease diagnosis, stratification, prognosis, metabolism, and therapeutic outcomes |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
WO2006050041A2 (en) | 2004-10-28 | 2006-05-11 | Ramot At Tel Aviv University Ltd. | Methods for reducing or inhibiting brain inflammation or for promoting neurogenesis |
PE20061152A1 (es) | 2004-12-15 | 2006-10-13 | Neuralab Ltd | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
JP2008524247A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのアミロイドβ抗体 |
EP1861422B1 (en) | 2005-03-05 | 2010-02-24 | Abbott GmbH & Co. KG | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
JP2006265189A (ja) * | 2005-03-24 | 2006-10-05 | Kyoto Univ | βアミロイドペプチド、及びそれを用いたアルツハイマー病治療薬又は予防薬のスクリーニング方法 |
ES2318918B1 (es) * | 2005-04-01 | 2010-02-16 | Biotherapix Molecular Medicines, S.L.U. | Anticuerpos humanos con capacidad de union al peptido beta-amiloide y sus aplicaciones. |
WO2006116192A2 (en) | 2005-04-21 | 2006-11-02 | Medarex, Inc. | Irta-1 antibodies and their uses |
PE20061323A1 (es) | 2005-04-29 | 2007-02-09 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos |
CA2657953A1 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
WO2007021255A1 (en) | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
CN101371261A (zh) | 2005-11-14 | 2009-02-18 | 纽约哥伦比亚大学理事会 | 神经发生的mri成像相关方法 |
CA2630964A1 (en) | 2005-11-22 | 2007-05-31 | The Trustees Of The University Of Pennsylvania | Antibody treatment of alzheimer's and related diseases |
KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
EP1963363A2 (en) | 2005-11-30 | 2008-09-03 | Abbott Laboratories | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins |
EP2808032B1 (en) | 2005-12-12 | 2018-08-01 | AC Immune S.A. | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8759297B2 (en) | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses. |
DK2426143T3 (en) | 2007-01-05 | 2017-09-11 | Univ Zuerich | Process for providing disease-specific binding molecules and targets |
CA2678963C (en) | 2007-02-23 | 2018-05-01 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
MX2009009926A (es) | 2007-03-13 | 2010-03-15 | Univ Zuerich | Anticuerpo tumor-especifico humano monoclonal. |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
JP2011526240A (ja) | 2007-04-18 | 2011-10-06 | ヤンセン アルツハイマー イミュノセラピー | 脳アミロイド血管症の予防および治療 |
JP2008309778A (ja) | 2007-05-11 | 2008-12-25 | Daiichi Sankyo Co Ltd | ポリペプチドの検出又は定量方法、及び装置 |
JP2010532976A (ja) | 2007-06-08 | 2010-10-21 | ユニヴェルシテ・ドゥ・ラ・メディテラネ | 膵臓腫瘍を治療するための組成物および方法 |
US8022268B2 (en) | 2007-06-11 | 2011-09-20 | The University Of Zurich | Transgenic animal model for alzheimer's disease |
SI2182983T1 (sl) | 2007-07-27 | 2014-09-30 | Janssen Alzheimer Immunotherapy | Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta |
EP2185160B1 (en) | 2007-08-31 | 2019-02-13 | Neurimmune Holding AG | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
EP2185592B1 (en) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
CA2700723A1 (en) | 2007-09-26 | 2009-04-02 | Amgen Inc. | Heparin-binding epidermal growth factor-like growth factor antigen binding proteins |
EP2195025B1 (en) | 2007-10-02 | 2013-11-06 | CSL Limited | Therapeutic antibody purification method and method of use |
CN101965365A (zh) | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
GB0720912D0 (en) | 2007-10-25 | 2007-12-05 | Univ Cardiff | Monoclonal Anitbody for APP |
WO2009056490A1 (en) | 2007-10-29 | 2009-05-07 | Innogenetics Nv | NEW ANTIBODIES SPECIFIC OF THE β-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS |
MY158903A (en) | 2007-11-16 | 2016-11-30 | Univ Rockefeller | Antibodies specific for the protofibril form of beta-amyloid protein |
CA2709354C (en) | 2007-12-21 | 2014-06-17 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
WO2009094592A2 (en) | 2008-01-23 | 2009-07-30 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
CN102936287B (zh) | 2008-02-08 | 2015-09-09 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
EP2282758B1 (en) | 2008-04-29 | 2018-11-21 | BioArctic AB | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
EP2321348A2 (en) | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
US20100196398A1 (en) | 2008-09-19 | 2010-08-05 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
PT2365804E (pt) | 2008-11-13 | 2015-09-16 | Modgene Llc | Redução da carga da beta-amiloide em tecido não cerebral |
ES2544569T3 (es) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Autoanticuerpos humanos anti alfa-sinucleina |
DK2419447T3 (en) | 2009-04-17 | 2017-09-25 | Immunas Pharma Inc | ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF |
US20110237537A1 (en) | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
EP2462162B1 (en) | 2009-08-06 | 2016-10-12 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
DK2462161T3 (en) | 2009-08-06 | 2017-06-06 | Immunas Pharma Inc | Antibodies specifically binding to A-beta oligomers and their use |
WO2011064225A1 (en) | 2009-11-24 | 2011-06-03 | Probiodrug Ag | Novel diagnostic method for the diagnosis of alzheimer's disease or mild cgnitive impairment |
WO2011072091A1 (en) | 2009-12-09 | 2011-06-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the cns |
WO2011076854A1 (en) | 2009-12-22 | 2011-06-30 | Probiodrug Ag | CLEAVAGE OF β-AMYLOID PRECURSOR PROTEIN |
GB2495036B (en) | 2010-07-07 | 2019-03-27 | Thermo Fisher Scient Gmbh | Kits for analyte mass spectrometry quantitation using a universal reporter |
PL3339323T3 (pl) | 2010-08-12 | 2020-05-18 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi N3pGlu amyloidu beta i ich zastosowania |
PL2627672T3 (pl) | 2010-10-11 | 2018-11-30 | Biogen International Neuroscience Gmbh | Ludzkie przeciwciała anty-tau |
US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
WO2012174262A2 (en) | 2011-06-14 | 2012-12-20 | Cenestra Llc | Formulations and methods of treating subjects having central nervous system, endocrine, inflammatory or cardiovascular disorders or at-risk thereof with highly purified omega-3 fatty acid formulations |
AU2012327211C9 (en) | 2011-10-28 | 2016-11-17 | Biogen International Neuroscience Gmbh | TDP-43 specific binding molecules |
US20130164367A1 (en) | 2011-12-08 | 2013-06-27 | The Board Of Regents Of The University Of Texas System | Treatment of neurodegenerative disease with creb-binding protein |
ITRM20120383A1 (it) | 2012-03-20 | 2013-09-21 | Uni Degli Studi Di Milano B Icocca | Metodo e kit per la rivelazione di anticorpi. |
EA201590459A1 (ru) | 2012-09-12 | 2015-11-30 | Нейриммьюн Холдинг Аг | Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение |
AU2013354968A1 (en) | 2012-12-07 | 2015-07-16 | Joseph Arndt | A method of reducing brain amyloid plaques using anti-AB antibodies |
US20140272950A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict ssri response |
US20140274764A1 (en) | 2013-03-15 | 2014-09-18 | Pathway Genomics Corporation | Method and system to predict response to treatments for mental disorders |
WO2015006475A1 (en) | 2013-07-12 | 2015-01-15 | Biogen Idec International Neuroscience Gmbh | Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
WO2015092077A1 (en) | 2013-12-20 | 2015-06-25 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
WO2015175769A1 (en) | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Methods for the detection of amyloid beta oligomers in biological samples |
WO2015191825A1 (en) | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Methods for the detection and measurement of amyloid beta in biological samples |
KR102643395B1 (ko) | 2014-07-29 | 2024-03-11 | 뉴리뮨 홀딩 아게 | 인간-유래의 항-헌팅틴(htt) 항체 및 그의 용도 |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
-
2009
- 2009-06-24 IL IL199534A patent/IL199534A/en active IP Right Grant
- 2009-08-05 CO CO09081882A patent/CO6230998A2/es active IP Right Grant
-
2012
- 2012-01-11 JP JP2012002761A patent/JP2012139219A/ja active Pending
- 2012-02-02 IL IL217923A patent/IL217923A/en active IP Right Grant
- 2012-12-17 US US13/717,152 patent/US9670272B2/en active Active
-
2013
- 2013-03-14 US US13/827,673 patent/US20130266585A1/en not_active Abandoned
- 2013-03-15 US US13/841,485 patent/US20130266586A1/en not_active Abandoned
- 2013-03-15 US US13/838,526 patent/US20130266514A1/en not_active Abandoned
- 2013-08-14 JP JP2013168464A patent/JP5876014B2/ja active Active
- 2013-11-29 CY CY20131101074T patent/CY1114953T1/el unknown
-
2014
- 2014-01-16 HR HRP20140049AT patent/HRP20140049T1/hr unknown
- 2014-07-02 US US14/322,096 patent/US20150147343A1/en not_active Abandoned
- 2014-12-12 JP JP2014251400A patent/JP6006284B2/ja active Active
-
2015
- 2015-03-13 JP JP2015050537A patent/JP5930502B2/ja active Active
-
2016
- 2016-02-29 JP JP2016038290A patent/JP2016116530A/ja active Pending
- 2016-03-10 US US15/066,304 patent/US9828420B2/en active Active
- 2016-09-08 JP JP2016175675A patent/JP2017060463A/ja not_active Withdrawn
-
2017
- 2017-05-12 US US15/593,845 patent/US10202445B2/en active Active
- 2017-08-02 HR HRP20171190TT patent/HRP20171190T1/hr unknown
- 2017-09-26 HR HRP20171440TT patent/HRP20171440T1/hr unknown
- 2017-10-24 US US15/791,632 patent/US10131708B2/en active Active
-
2018
- 2018-10-09 US US16/154,920 patent/US20190263896A1/en not_active Abandoned
- 2018-12-19 US US16/226,409 patent/US20190153082A1/en not_active Abandoned
-
2022
- 2022-01-05 US US17/569,019 patent/US20220403011A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20160289310A1 (en) | 2016-10-06 |
CO6230998A2 (es) | 2010-12-20 |
JP2015120744A (ja) | 2015-07-02 |
JP2017060463A (ja) | 2017-03-30 |
US20190263896A1 (en) | 2019-08-29 |
HRP20171440T1 (hr) | 2017-11-03 |
US20220403011A1 (en) | 2022-12-22 |
US20170283491A1 (en) | 2017-10-05 |
IL217923A (en) | 2015-10-29 |
US20130266586A1 (en) | 2013-10-10 |
US20130216555A1 (en) | 2013-08-22 |
JP5930502B2 (ja) | 2016-06-08 |
US9670272B2 (en) | 2017-06-06 |
HRP20140049T1 (hr) | 2014-02-28 |
US9828420B2 (en) | 2017-11-28 |
JP6006284B2 (ja) | 2016-10-12 |
JP2015110574A (ja) | 2015-06-18 |
US20180134773A1 (en) | 2018-05-17 |
IL199534A (en) | 2013-01-31 |
CY1114953T1 (el) | 2016-12-14 |
US20190153082A1 (en) | 2019-05-23 |
JP5876014B2 (ja) | 2016-03-02 |
US20130266514A1 (en) | 2013-10-10 |
US10131708B2 (en) | 2018-11-20 |
US20150147343A1 (en) | 2015-05-28 |
US10202445B2 (en) | 2019-02-12 |
JP2012139219A (ja) | 2012-07-26 |
JP2016116530A (ja) | 2016-06-30 |
US20130266585A1 (en) | 2013-10-10 |
JP2013226162A (ja) | 2013-11-07 |
IL217923A0 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171190T1 (hr) | Protutijelo protiv beta-amiloida i njegove upotrebe | |
IL299072A (en) | Antibodies and methods for using them | |
AR059432A1 (es) | Anticuerpos anti-fgf19 y metodos que usan estos | |
JP2013121353A5 (hr) | ||
HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
HRP20191342T1 (hr) | Anti-phf-tau antitijela i njihove upotrebe | |
HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
IL266893A (en) | Meditops and antibodies bind meditops and their use | |
BR112019009316A2 (pt) | anticorpo antirreceptor de transferrina humana, proteína de fusão, fragmento de dna, vetor de expressão, célula de mamífero, complexo de composto farmacologicamente ativo e de anticorpo antirreceptor de transferrina humana, usos do anticorpo antirreceptor de transferrina humana e da proteína de fusão, e, métodos para tratamento de um distúrbio do sistema nervoso central e de uma doença do sistema nervoso central que acompanha a doença de pompe, a síndrome de hurler ou a síndrome de hurler-scheie. | |
RU2019118359A (ru) | Антитело к cd73 человека | |
JP2011526785A5 (hr) | ||
AR058932A1 (es) | Anticuerpos anti-ephb4 y metodos que usan estos | |
AR108663A1 (es) | ANTICUERPOS CONTRA a-SINUCLEÍNA Y SUS USOS | |
AR065271A1 (es) | Anticuerpos anti-robo4 y sus usos | |
PE20090161A1 (es) | Anticuerpos monoclonales anti cxcl13 | |
HRP20110599T1 (hr) | Antitijela protiv toksina clostridium difficile i njihove primjene | |
IL173323A0 (en) | Antibodies directed to parathyroid hormone (pth) and uses thereof | |
NZ598202A (en) | High affinity human antibodies to human angiopoietin-2 | |
JP2013545734A5 (hr) | ||
JP2012100677A5 (hr) | ||
JP2010523541A5 (hr) | ||
WO2008112004A3 (en) | ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF | |
RU2015142815A (ru) | Лечение рака с использованием антител, связывающихся с поверхностным grp78 | |
RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) |